Covered recipient · General Payments record
MARC BLOOMENSTEIN
Eye and Vision Services Providers Optometrist
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$130,158.94
245 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $44,450.68 | 33 |
| Honoraria | $29,700.00 | 9 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,800.00 | 12 |
| Travel and Lodging | $18,445.71 | 75 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,850.00 | 3 |
| Food and Beverage | $3,912.55 | 113 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Allergan Inc. | $41,151.44 | 115 |
| Sun Pharmaceutical Industries Inc. | $36,480.24 | 41 |
| Johnson & Johnson Surgical Vision, Inc. | $29,730.49 | 31 |
| Bausch & Lomb, a division of Bausch Health US, LLC | $9,823.73 | 22 |
| Reichert, Inc. | $6,900.00 | 12 |
| Novartis Pharmaceuticals Corporation | $1,553.90 | 3 |
| TissueTech, Inc. | $1,316.58 | 2 |
| Shire North American Group Inc | $1,083.14 | 5 |
| Alcon Vision LLC | $898.12 | 4 |
| Alcon Research LLC | $840.00 | 1 |
| Dompe US, Inc. | $176.97 | 2 |
| Sight Sciences, Inc. | $100.77 | 2 |
| Mallinckrodt Enterprises LLC | $59.34 | 2 |
| Eyevance Pharmaceuticals LLC | $17.63 | 1 |
| STAAR SURGICAL COMPANY | $15.19 | 1 |
| Johnson & Johnson Vision Care, Inc. | $11.40 | 1 |
Page 2 of 5; records 51–100 of 245 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARC BLOOMENSTEIN
NPI 1568428910 · CMS profile ID 25861
Eye and Vision Services Providers / Optometrist
SCOTTSDALE, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 245 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1568428910?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARC BLOOMENSTEIN, NPI 1568428910, CMS profile ID 25861. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 245 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568428910?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). MARC BLOOMENSTEIN, NPI 1568428910, CMS profile ID 25861. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 245 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568428910?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- MARC BLOOMENSTEIN, NPI 1568428910, CMS profile ID 25861, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 245 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1568428910?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
245 matching records · $130,158.94 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 245.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bausch & Lomb, a division of Bausch Health US, LLC | $21.35 | 11/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684386615 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $6,750.00 | 10/29/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932789 | CMS |
| Allergan Inc. | $6.24 | 10/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131353 | CMS |
| Allergan Inc. | $31.20 | 10/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131355 | CMS |
| Allergan Inc. | $27.00 | 10/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131357 | CMS |
| Allergan Inc. | $124.10 | 10/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131359 | CMS |
| Allergan Inc. | $619.60 | 10/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131361 | CMS |
| Allergan Inc. | $134.47 | 10/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131363 | CMS |
| Allergan Inc. | $2,500.00 | 10/18/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131365 | CMS |
| Allergan Inc. | $23.96 | 10/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131367 | CMS |
| Allergan Inc. | $17.32 | 10/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131351 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $6,750.00 | 10/14/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932791 | CMS |
| Sun Pharmaceutical Industries Inc. | $5.07 | 10/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590467 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $52.71 | 10/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932785 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $2,000.68 | 10/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932787 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $54.81 | 10/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932793 | CMS |
| Reichert, Inc. | $500.00 | 10/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 623745913 | CMS |
| Allergan Inc. | $50.00 | 09/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131349 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $50.00 | 09/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932761 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $35.00 | 09/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932769 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $35.00 | 09/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932771 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $23.79 | 09/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932773 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $417.94 | 09/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932755 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $3.26 | 09/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932763 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $41.68 | 09/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932775 | CMS |
| Dompe US, Inc. | $121.90 | 09/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703174849 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $3.50 | 09/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932765 | CMS |
| Allergan Inc. | $6.73 | 09/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131347 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $1,298.97 | 09/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932753 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $30.36 | 09/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932759 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $49.90 | 09/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932767 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $34.50 | 09/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932777 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $66.42 | 09/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932779 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $123.96 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932757 | CMS |
| Johnson & Johnson Surgical Vision, Inc. | $29.07 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655932781 | CMS |
| TissueTech, Inc. | $66.58 | 09/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698622551 | CMS |
| Bausch & Lomb, a division of Bausch Health US, LLC | $4.51 | 09/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684386613 | CMS |
| Allergan Inc. | $3.76 | 09/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131345 | CMS |
| Sun Pharmaceutical Industries Inc. | $258.77 | 09/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590539 | CMS |
| Sun Pharmaceutical Industries Inc. | $401.60 | 09/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590541 | CMS |
| Sun Pharmaceutical Industries Inc. | $76.03 | 09/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590543 | CMS |
| Sun Pharmaceutical Industries Inc. | $4,700.00 | 09/13/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590545 | CMS |
| Allergan Inc. | $2.65 | 09/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131309 | CMS |
| Allergan Inc. | $2.75 | 09/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131311 | CMS |
| Allergan Inc. | $34.80 | 09/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131313 | CMS |
| Allergan Inc. | $4.00 | 09/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131315 | CMS |
| Allergan Inc. | $17.48 | 09/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131317 | CMS |
| Allergan Inc. | $14.64 | 09/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131319 | CMS |
| Allergan Inc. | $5.25 | 09/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131321 | CMS |
| Allergan Inc. | $20.03 | 09/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670131323 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $264,073.50 | 27 |
| PY2024 | Principal investigator | $148,060.00 | 10 |
| PY2023 | Principal investigator | $65,884.50 | 3 |
| PY2022 | Principal investigator | $235,930.50 | 6 |
| PY2021 | Principal investigator | $112,295.00 | 3 |
| PY2020 | Principal investigator | $28,116.14 | 13 |
| PY2019 | Principal investigator | $48,967.00 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
27 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Oyster Point Pharma, Inc. | $1,016.00 | 12/16/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia (VEGA-3) | No dispute reported | 06/30/2026 | 1238523014 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $1,316.00 | 12/12/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) | No dispute reported | 06/30/2026 | 1238522992 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $11,536.00 | 12/12/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523042 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $2,632.00 | 11/17/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) | No dispute reported | 06/30/2026 | 1238522996 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $6,460.00 | 11/17/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia (VEGA-3) | No dispute reported | 06/30/2026 | 1238523018 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $8,168.00 | 10/16/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia (VEGA-3) | No dispute reported | 06/30/2026 | 1238523012 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $13,316.00 | 10/16/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia (VEGA-3) | No dispute reported | 06/30/2026 | 1238523016 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $3,948.00 | 10/15/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) | No dispute reported | 06/30/2026 | 1238522994 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $2,500.00 | 10/15/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523040 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $2,680.00 | 09/29/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) | No dispute reported | 06/30/2026 | 1238523006 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $3,948.00 | 09/15/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523036 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $11,964.00 | 08/22/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) | No dispute reported | 06/30/2026 | 1238523010 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $2,632.00 | 08/18/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523038 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $12,450.00 | 07/23/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) | No dispute reported | 06/30/2026 | 1238523008 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $8,554.00 | 07/23/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523034 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $7,508.00 | 06/12/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523032 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $7,230.00 | 06/10/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) | No dispute reported | 06/30/2026 | 1238522998 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $8,718.00 | 05/01/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) | No dispute reported | 06/30/2026 | 1238523000 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $11,786.00 | 04/29/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523028 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $16,088.00 | 04/01/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) | No dispute reported | 06/30/2026 | 1238523002 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $16,090.00 | 04/01/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) | No dispute reported | 06/30/2026 | 1238523004 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $11,252.00 | 04/01/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523024 |
| Principal investigator 1 | Sight Sciences, Inc. | $35,433.50 | 03/20/2025 | Non-covered Recipient Entity MRB Eye Consultants | Prospective Randomized Masked Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Signs and Symptoms of Dry Eye Disease (SAHARA) | No dispute reported | 06/30/2026 | 1244586207 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $7,358.00 | 02/14/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523026 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $14,750.00 | 02/14/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523030 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $18,142.00 | 01/13/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523020 |
| Principal investigator 1 | Oyster Point Pharma, Inc. | $16,598.00 | 01/13/2025 | Non-covered Recipient Entity MRB Eye Consultants, LLC | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) | No dispute reported | 06/30/2026 | 1238523022 |